Key facts

Invented name
Bilaxten and associated names
Active Substance
Bilastine
Therapeutic area
Ophthalmology
Decision number
P/0506/2022
PIP number
EMEA-000347-PIP02-16-M04
Pharmaceutical form(s)
Eye drops, solution
Condition(s) / indication(s)
Treatment of allergic conjunctivitis
Route(s) of administration
Ocular use
Contact for public enquiries

FAES FARMA, S.A.

Tel. +34 944818300
E-mail: ieguidazu@faes.es

Decision type
PM: decision on the application for modification of an agreed PIP
Decision date

Decision

How useful do you find this page?